comparemela.com

Latest Breaking News On - David samuel dicapua siegel - Page 1 : comparemela.com

Dr Siegel on the Rationale for Investigating KID in Multiple Myeloma

David Samuel Dicapua Siegel, MD, discusses a trial of carfilzomib, iberdomide, and dexamethasone in newly diagnosed, transplant-eligible multiple myeloma.

David samuel dicapua siegelHackensack university medical centerJohn theurer cancer centerDivision of multiple myelomaMultiple myelomaNd dexamethasoneNewly diagnosedTransplant eligible multiple myeloma

Dr Siegel on the Importance of Closing the Gaps in Cancer Care

David Samuel Dicapua Siegel, MD, discusses the importance of closing the gaps in cancer care and spreading awareness of current treatment inequities in oncology through campaigns such as World Cancer Day.

New yorkUnited statesDavid samuel dicapua siegelHackensack meridian healthHackensack university medical centerMyeloma divisionJohn theurer cancer centerWorld cancerCancer dayWorld cancer dayScare gapJohn theurer cancer centerHackensack university medical centerOnclive tvDisparities in cancer care

Dr Siegel on the Use of Carfilzomib/Iberdomide/Dexamethasone Therapy in Multiple Myeloma

David Samuel Dicapua Siegel, MD, discusses the potential use of carfilzomib, iberdomide, and dexamethasone in newly diagnosed multiple myeloma.

David samuel dicapua siegelHackensack university medical centerMyeloma divisionJohn theurer cancer centerJohn theurer cancer centerHackensack university medical centerOnclive tvMultiple myeloma

Dr Siegel on the Importance of Real-World Data in Patients With Multiple Myeloma

David Samuel Dicapua Siegel, MD, emphasizes the importance of real-world evidence when treating patients with relapsed/refractory multiple myeloma.

David samuel dicapua siegelHackensack university medical centerMyeloma divisionJohn theurer cancer centerHackensack university medical centerOnclive tvOvarian cancer

vimarsana © 2020. All Rights Reserved.